An antibody that blocks pancreatic cancer immune-evasion slows tumour growth and could provide a new treatment approach for pancreatic ductal adenocarcinoma.
SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer - Nature
SPP1 plasma levels increase in late-stage pancreatic ductal adenocarcinoma and in KPCY mouse models, correlating with mesenchymal marker analyses and organoid-based tumor assays.